Oncology Pipeline – Page 2

Merck & Co. Expands Oncology Pipeline with Kelun-Biotech ADCs

1 year ago talkbio0Tagged Antibody-Drug, Antibody-Drug Conjugates, Immunostimulating conjugate (antigen), Kelun-Biotech, Malignant Neoplasms, Merck & Co., Oncology Pipeline

Merck & Co., Kelun-Biotech, Antibody-Drug Conjugates (ADCs), Cancer Treatment, Oncology Pipeline

Merck & Co., Daiichi Sankyo Strengthen Partnership with New DLL3 Cancer Drug Agreement

1 year ago talkbio0Tagged Antibody-Drug, Daiichi, DLL3, DLL3 gene, Immunostimulating conjugate (antigen), Merck & Co., MK-6070, Neoplasms, Neurosecretory Systems, Oncology Pipeline, Sankyo, Small cell carcinoma of lung, T-Lymphocyte

Merck & Co., Daiichi Sankyo, DLL3, T-cell engager, MK-6070, small cell lung cancer, neuroendocrine tumors, antibody-drug conjugates, oncology pipeline

Merck KGaA Discontinues Xevinapant Program in Locally Advanced Head and Neck Cancer Due to Phase III Trial Failure

1 year ago talkbio0Tagged Apoptosis, Cancer of Neck, Merck KGaA, Oncology Pipeline, Phase 3 Clinical Trials, proteins inhibitor, X-Ray Vision study

Merck KGaA, xevinapant, Phase III trial, head and neck cancer, TrilynX study, X-Ray Vision study, oncology pipeline, apoptosis proteins inhibitor

Ono Pharmaceutical Strengthens Oncology Portfolio with Acquisition of Deciphera Pharmaceuticals for $2.4 Billion

2 years ago talkbio0Tagged Acquisition (action), cancer treatments, Clinical Development, Collaboration, Deciphera, Dosage Forms, expansion, Generalized, Market, Oncology Pipeline, strategic

Ono Pharmaceutical, Deciphera Pharmaceuticals, oncology pipeline, acquisition, $2.4 billion, cancer treatments, kinase inhibitors, strategic expansion, global market, clinical development, collaboration.